Technical Trend Overview and Price Movement
The stock closed at ₹1,166.50 on 24 Jul 2026, down 1.39% from the previous close of ₹1,183.00. Intraday volatility was evident with a low of ₹1,080.05 and a high of ₹1,171.20, reflecting investor uncertainty. The 52-week range remains broad, with a high of ₹1,414.40 and a low of ₹1,080.05, underscoring the stock’s susceptibility to market swings over the past year.
Dr Reddys Laboratories’ technical trend has shifted from a sideways pattern to mildly bearish, signalling a potential weakening in price momentum. This shift is corroborated by several key technical indicators across different timeframes.
MACD Signals Indicate Bearish Pressure
The Moving Average Convergence Divergence (MACD) indicator, a widely used momentum oscillator, shows a bearish signal on the weekly chart and a mildly bearish stance on the monthly chart. The weekly MACD line has crossed below its signal line, suggesting increasing downward momentum in the short term. Meanwhile, the monthly MACD remains mildly bearish, indicating that while the longer-term trend is not decisively negative, caution is warranted.
RSI Remains Neutral, Offering No Clear Signal
The Relative Strength Index (RSI) on both weekly and monthly charts currently offers no definitive signal, hovering in a neutral zone. This suggests that the stock is neither overbought nor oversold, implying that momentum could swing in either direction depending on upcoming market catalysts or sector developments.
Bollinger Bands Confirm Bearish Bias
Bollinger Bands, which measure volatility and price levels relative to moving averages, are signalling bearish conditions on both weekly and monthly timeframes. The stock price has recently touched or breached the lower band on the weekly chart, indicating increased selling pressure and potential continuation of the downward trend.
Moving Averages Show Mildly Bullish Daily Momentum
Contrasting the broader bearish signals, daily moving averages present a mildly bullish picture. The stock price remains above its short-term moving averages, suggesting some underlying support and potential for short-term rebounds. However, this bullishness is tempered by the weekly and monthly bearish indicators, highlighting a divergence between short-term and longer-term momentum.
Additional Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) oscillator is mildly bearish on the weekly chart but bullish on the monthly, reinforcing the mixed momentum signals. Dow Theory assessments align with a mildly bearish outlook on both weekly and monthly scales, indicating that the broader market trend for the stock is under pressure. On-Balance Volume (OBV) also reflects mildly bearish sentiment, with volume trends supporting the recent price declines.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Comparative Performance Against Sensex
Dr Reddys Laboratories’ recent returns have lagged the benchmark Sensex across most short- and medium-term periods. Over the past week, the stock declined by 4.69%, significantly underperforming the Sensex’s 1.03% drop. The one-month return was down 10.36%, while the Sensex gained 0.25% in the same period. Year-to-date, the stock is down 8.23%, slightly outperforming the Sensex’s 10.36% decline. Over one year, the stock’s loss of 6.50% is marginally better than the Sensex’s 7.66% fall.
Longer-term returns show a more positive picture, with the stock delivering a 10.30% gain over three years compared to the Sensex’s 14.56%, and a 7.55% return over five years versus the Sensex’s 44.20%. Over a decade, Dr Reddys Laboratories has appreciated by 61.77%, though this is well below the Sensex’s 174.76% gain, reflecting the stock’s more modest growth trajectory relative to the broader market.
Mojo Score and Grade Downgrade
MarketsMOJO’s proprietary scoring system currently assigns Dr Reddys Laboratories a Mojo Score of 36.0, categorising it as a Sell. This represents a downgrade from the previous Hold rating, effective from 13 Jul 2026. The downgrade reflects the deteriorating technical indicators and the stock’s underperformance relative to the sector and benchmark indices. The company remains classified as a large-cap within the Pharmaceuticals & Biotechnology sector, but the technical and momentum signals suggest caution for investors.
Investment Implications and Outlook
The mixed technical signals for Dr Reddys Laboratories suggest a cautious approach. While daily moving averages hint at short-term support, the broader weekly and monthly indicators point to a mildly bearish momentum that could weigh on the stock in the near term. Investors should monitor key support levels near the recent low of ₹1,080.05 and watch for any reversal signals in MACD or RSI that might indicate a change in trend.
Given the stock’s recent underperformance against the Sensex and the downgrade in Mojo Grade, investors may consider re-evaluating their exposure, especially if the broader Pharmaceuticals & Biotechnology sector faces headwinds. The stock’s long-term fundamentals remain intact, but technical momentum currently favours a defensive stance.
Dr Reddys Laboratories Ltd or something better? Our SwitchER feature analyzes this large-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Context
The Pharmaceuticals & Biotechnology sector continues to face volatility amid regulatory scrutiny, pricing pressures, and evolving global healthcare demands. Dr Reddys Laboratories, as a large-cap entity, is not immune to these challenges. The stock’s technical deterioration may reflect broader sector sentiment as well as company-specific factors such as pipeline developments and earnings outlook.
Investors should weigh these technical signals alongside fundamental analysis and sector trends before making allocation decisions. The current mildly bearish momentum suggests that patience and selective entry points may be prudent strategies in the near term.
Conclusion
Dr Reddys Laboratories Ltd’s recent technical parameter changes highlight a shift towards mildly bearish momentum, with key indicators such as MACD and Bollinger Bands signalling caution. Despite some short-term bullishness in daily moving averages, the overall technical landscape advises vigilance. The downgrade in Mojo Grade to Sell further emphasises the need for careful evaluation by investors. While the stock’s long-term prospects remain supported by its large-cap status and sector positioning, the current technical environment suggests a defensive stance until clearer signs of trend reversal emerge.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
